These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

760 related articles for article (PubMed ID: 18261916)

  • 61. [VEGF (vascular endothelial growth factor) concentration in serum and pleural fluid of patients with pleural malignancy and pleural tuberculosis].
    Ziora D; Sielska-Spytek E; Dworniczak S; Oklek K; Kozielski J
    Pneumonol Alergol Pol; 2002; 70(9-10):458-67. PubMed ID: 12710098
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Increased survivin mRNA in malignant pleural effusion is significantly correlated with survival.
    Lan CC; Wu YK; Lee CH; Huang YC; Huang CY; Tsai YH; Huang SF; Tsao TC
    Jpn J Clin Oncol; 2010 Mar; 40(3):234-40. PubMed ID: 19933689
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Value of the determination of CA 15-3 in the diagnosis of malignant pleural effusion].
    Romero S; Hernández L; Salar A; García-Sevila R; Espasa MA; Martín-Serrano C
    Rev Clin Esp; 1992 Apr; 190(7):339-43. PubMed ID: 1620918
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Osteopontin is upregulated in malignant and inflammatory pleural effusions.
    Moschos C; Porfiridis I; Psallidas I; Kollintza A; Stathopoulos GT; Papiris SA; Roussos C; Kalomenidis I
    Respirology; 2009 Jul; 14(5):716-22. PubMed ID: 19476604
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions.
    Miédougé M; Rouzaud P; Salama G; Pujazon MC; Vincent C; Mauduyt MA; Reyre J; Carles P; Serre G
    Br J Cancer; 1999 Nov; 81(6):1059-65. PubMed ID: 10576665
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical evaluation of four tumor markers in malignant and benign pleural effusions.
    Toumbis M; Chondros K; Ferderigos AS; Daganou M; Dema A; Dalamaga A; Kakari S; Stringou E
    Anticancer Res; 1992; 12(4):1267-70. PubMed ID: 1503419
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Acute phase markers for the differentiation of infectious and malignant pleural effusions.
    Kiropoulos TS; Kostikas K; Oikonomidi S; Tsilioni I; Nikoulis D; Germenis A; Gourgoulianis KI
    Respir Med; 2007 May; 101(5):910-8. PubMed ID: 17270413
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Clinical evaluation of various tumor markers in pleural effusion and in the serum].
    Jibiki K; Abe Y; Takeda M; Iwachika C; Odagiri E; Demura R; Demura H
    Gan No Rinsho; 1989 Aug; 35(9):991-8. PubMed ID: 2769951
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications.
    Fiorelli A; Vicidomini G; Di Domenico M; Napolitano F; Messina G; Morgillo F; Ciardiello F; Santini M
    Interact Cardiovasc Thorac Surg; 2011 Mar; 12(3):420-4. PubMed ID: 21172937
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Diagnostic significance of gamma-interferon in tuberculous pleurisy.
    Poyraz B; Kaya A; Ciledağ A; Oktem A; Gönüllü U
    Tuberk Toraks; 2004; 52(3):211-7. PubMed ID: 15351932
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.
    Schneider J; Velcovsky HG; Morr H; Katz N; Neu K; Eigenbrodt E
    Anticancer Res; 2000; 20(6D):5053-8. PubMed ID: 11326667
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Plasma TM2-PK levels in mycosis fungoides patients.
    Hapa A; Erkin G; Hasçelik G; Pektaş D; Arslan U
    Arch Dermatol Res; 2011 Jan; 303(1):35-40. PubMed ID: 20927531
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Diagnostic value of three tumor markers determined in pleural effusions.
    Conejo JR; Benedito JE; Jimenez A; Menchen M; Cano J; Granizo V; Larrodera L
    Eur J Clin Chem Clin Biochem; 1996 Feb; 34(2):139-42. PubMed ID: 8833646
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
    Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J
    Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical utility of vascular endothelial growth factor in diagnosing malignant pleural effusions.
    Shu J; Sun G; Liu H; Liu J
    Acta Oncol; 2007; 46(7):1004-11. PubMed ID: 17917830
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [M2-type pyruvate kinase in the diagnosis of hepatocarcinoma--a pilot study].
    Liu JB
    Zhonghua Zhong Liu Za Zhi; 1990 May; 12(3):166-9. PubMed ID: 2174328
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diagnosis of tuberculous pleuritis by the measurement of soluble interleukin 2 receptor in pleural fluid.
    Porcel JM; Gázquez I; Vives M; Pérez B; Rubio M; Rivas MC
    Int J Tuberc Lung Dis; 2000 Oct; 4(10):975-9. PubMed ID: 11055766
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Matrix metalloproteinases and their inhibitors in lung cancer with malignant pleural effusion].
    Moche M; Hui DS; Huse K; Chan KS; Choy DK; Scholz GH; Gosse H; Winkler J; Schauer J; Sack U; Hoheisel G
    Pneumologie; 2005 Aug; 59(8):523-8. PubMed ID: 16110415
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The diagnostic significance of the detection of cytokeratin 19 mRNA by quantitative RT-PCR in benign and malignant pleural effusions.
    Xu F; Chen J; Shen HH; Wang XD; Shan J
    J Zhejiang Univ Sci; 2004 Oct; 5(10):1286-9. PubMed ID: 15362202
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions.
    Hamed EA; El-Noweihi AM; Mohamed AZ; Mahmoud A
    Respirology; 2004 Mar; 9(1):81-6. PubMed ID: 14982607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.